Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News SANOFI SNY

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.


Recent & Breaking News (NDAQ:SNY)

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis

PR Newswire November 11, 2022

Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old

PR Newswire October 11, 2022

Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes

PR Newswire October 6, 2022

Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis

PR Newswire September 28, 2022

Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet

PR Newswire September 15, 2022

Dupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis

PR Newswire September 8, 2022

Late-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma

PR Newswire September 5, 2022

Sanofi higher dose flu vaccines preferentially recommended for adults 65+ in CDC Morbidity and Mortality Weekly Report

PR Newswire August 26, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sanofi - SNY

Newsfile August 12, 2022

Public health experts underscore importance of flu vaccinations to help reduce health inequities among high-risk populations

PR Newswire August 12, 2022

Sanofi appoints new Heads of U.S. General Medicines, and North America Vaccines and Consumer Healthcare

PR Newswire August 3, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

PR Newswire August 1, 2022

Sanofi partners with Howard University in an unprecedented pharmacy fellowship program

PR Newswire July 26, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

PR Newswire July 21, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

PR Newswire July 13, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

Newsfile July 11, 2022

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Sanofi with Losses of $100,000 to Contact the Firm

Newsfile July 7, 2022

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Sanofi with Losses of $100,000 to Contact the Firm

Newsfile July 6, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

PR Newswire July 5, 2022

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Sanofi with Losses of $100,000 to Contact the Firm

Business Wire July 5, 2022